Best of Hematology and Breast Cancer 2025, Seattle

Seattle, WA US
January 3, 2025 to January 4, 2025

The Best of Hematology and Breast Cancer 2025 conference in Seattle is a CME-accredited, in-person event providing healthcare professionals with the latest updates in managing hematology and breast cancer. Drawing insights from the 66th ASH Annual Meeting (ASH24) and the San Antonio Breast Cancer Symposium (SABCS24), the conference features expert presentations on recent research and its clinical implications.

Focusing on a multidisciplinary approach, the event aims to integrate new advancements into patient-centered care. Designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other professionals, attendees will engage with colleagues and experts to critically evaluate data and improve patient outcomes.

The Best of Hematology and Breast Cancer 2025, Seattle, is an educational activity planned by the Binaytara Foundation. Neither Binaytara Foundation nor this activity are affiliated with the American Society of Hematology (ASH) or the San Antonio Breast Cancer Symposium (SABCS).

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Organizing Committee

Conference Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Co-Chairs:

Fengting Yan, MD, FACP  - Swedish Cancer Institute

Andrew J. Cowan, MD - Fred Hutch Cancer Center

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Summarize the latest updates from ASH24 and SABCS24, focusing on their implications for clinical practice in managing hematologic disorders and breast cancer.
  • Assess new therapeutic options for benign and malignant hematologic disorders and breast cancer, including appropriate indications and contraindications presented at ASH24 and SABCS24.
  • Examine the study design, primary endpoints, and impact of recent and ongoing clinical trials from ASH24 and SABCS24 that have influenced current standards of care.
  • Incorporate evolving diagnostic, prognostic, and therapeutic strategies from ASH24 and SABCS24 into patient management for hematologic disorders and breast cancer.
  • Apply emerging data from clinical trials and updated expert guidelines from ASH24 and SABCS24 to individualize patient management strategies.

Hotel Room Reservation

A limited number of guestrooms are reserved at the Grand Hyatt Seattle for the participants of this meeting at a discounted rate of $179 per night. The room rate does not include any additional fees or applicable taxes.

Please use the link below to reserve your room for the discounted rate. The rate is good through Tuesday December 3, 2024

Booking link coming soon...

Parking

The hotel offers overnight valet parking for $68.

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

You may also be interested in

Summit on Cancer Health Disparities (SCHD25)

The Summit on Cancer Health Disparities 2025 (SCHD25) is a premier annual event focused on addressing cancer health disparities. The conference serves to bridge research and practice, offering practical strategies to improve cancer care delivery and outcomes.
Course summary
Available credit: 
  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
Course opens: 
08/04/2024
Course expires: 
04/04/2025
Event starts: 
01/03/2025 - 4:00pm PST
Event ends: 
01/04/2025 - 4:30pm PST
Cost:
$250.00
Add to calendar: 

DAY 1 – Friday, January 3, 2025

All times are listed in Pacific Time (PT)

02:00 PM – 03:00 PM  Registration, Networking, & Exhibits

03:00 PM – 04:00 PM  Session 1: Case-Based Discussion: Classical Hematology

Session Chair: David Aboulafia, MD

03:00 PM – 03:15 PM  HUS/TTP - Livia Hegerova, MD

03:15 PM – 03:30 PM  PNH - Matthew Schwede, MD

03:30 PM – 03:45 PM  Anemia - David Aboulafia, MD

03:45 PM – 04:00 PM  Bone Marrow Failure - 

04:00 PM – 05:00 PM  Session 2: Case-Based Discussion: Bleeding and Clotting Disorder

Session Chair: 

04:00 PM – 04:30 PM  Bleeding Disorders - Jill Johnsen, MD

04:30 PM – 05:00 PM  Clotting Disorders - 

05:00 PM – 06:00 PM  Reception, Networking, and Exhibits

 

DAY 2 – Saturday, January 4, 2025

07:00 AM – 08:00 AM  Registration, Exhibits & Breakfast

08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:30 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA

08:30 AM – 09:30 AM  Session 3: Acute Leukemia

Session Chair: Roland Walter, MD, PhD, MS

08:30 AM – 09:00 AM  Acute Myeloid Leukemia/MDS - Roland Walter, MD, PhD, MS

09:00 AM – 09:30 AM  Acute Lymphoblastic Leukemia - Ryan Cassaday, MD

09:30 AM – 10:45 AM  Session 4: Lymphoma

Session Chair: Mazyar Shadman, MD, MPH

09:30 AM – 09:55 AM  B-Cell Lymphoma - Mengyang Di, MD, PhD

09:55 AM – 10:20 AM  CLL - Bita Fakhri, MD, MPH

10:20 AM – 10:45 AM  T-Cell Lymphoma - Christina Poh, MD

10:45 AM – 11:00 AM  Break & Exhibits

11:00 AM – 12:00 PM  Session 5: Multiple Myeloma

Session Chair: Mary Kwok, MD

11:00 AM – 11:30 AM  Frontline Therapy of Multiple Myeloma - Rahul Banerjee, MD, FACP

11:30 AM – 12:00 PM  Relapsed/Recurrent Multiple Myeloma - Danai Dima, MD 

12:00 PM – 01:00 PM  Lunch & Exhibits

01:00 PM – 02:00 PM Session 6: Hematologic Malignancies

Session Chairs: Jerald Radich, MD

01:00 PM – 01:30 PM  Myeloproliferative Neoplasms - Rachel B. Salit, MD

01:30 PM – 02:00 PM  Cellular Therapy - Alexandre V. Hirayama, MD

02:00 PM – 02:15 PM  Break & Exhibits

02:15 PM – 03:45 PM  Session 7: Updates in Management of Breast Cancer

Session Chair:  William R. Gwin III, MD

02:15 PM – 02:35 PM  HER2 Positive Breast Cancer - William R. Gwin III, MD

02:35 PM – 02:55 PM  Triple Negative and HER2 Low Breast Cancer - Mei Wei, MD

02:55 PM – 03:15 PM  HR Positive Breast Cancer - Vidhya Nair, DO

03:15 PM - 03:35 PM  De-Escalation of breast surgery and/or radiation -

03:35 PM - 03:45 PM  Q&A

03:45 PM – 04:15 PM  Session 8: Tumor Board-Style Case-Based Discussion: Breast Cancer

Session Chair: Fengting Yan, MD, FACP

03:45 PM – 03:55 PM  HER2 Low and Ultralow Disease - Darien Reed-Perino, MD, PhD

03:55 PM – 04:05 PM  High Risk Early Stage Breast Cancer - Xiaowen Wang, MD, PhD

04:05 PM – 04:15 PM  Panel Discussion - Guobin Song, MD; Mei Wei, MD ; Vidhya Nair, DO; William R. Gwin III, MD

04:15 PM – 05:00 PM  Session 9 - HRT Debate: Is it Safe?

Session Chair: Michaela L. Tsai, MD

04:15 PM – 04:20 PM  HRT Safety & Efficacy Overview -  

04:20 PM – 04:30 PM  Yes - Fernanda B. Musa, MD; Ashley E. Fuller, MD

04:30 PM – 04:40 PM  No - Michaela L. Tsai, MD; Fengting Yan, MD, FACP

04:40 PM – 05:00 PM  Panel Discussion - Michaela L. Tsai, MD; Lili A. Sacks, MD; Ashley E. Fuller, MD

05:00 PM  Adjourn

Grand Hyatt Seattle
721 Pine St
Seattle, WA 98101
United States

Hotel Room Reservation

A limited number of guestrooms are reserved at the Grand Hyatt Seattle for the participants of this meeting at a discounted rate of $179 per night. The room rate does not include any additional fees or applicable taxes.

CUTOFF - Tuesday December 11th, 2024

Please use the link below to reserve your room for the discounted rate. The rate is good through Tuesday December 11th, 2024

https://www.hyatt.com/en-US/group-booking/SEAGH/G-BIN4

Parking

The hotel offers overnight valet parking for $68.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Andrew Cowan, MD

has a financial relationship (Independent contractor) with Nektar;.
has a financial relationship (Professional Services) with Adaptive Biotech;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Independent contractor) with Harpoon;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Independent contractor) with Adaptive Biotechnology;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Independent contractor) with Janssen;.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.
Session Chair(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Jerald Radich, MD

has a financial relationship (Stock Options) with Biofidelity;.
has a financial relationship (Other) with HTG;.

Roland Walter, MD PhD MS

has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with ImmunoGen;.
has a financial relationship (Grant Or Contract) with Celgene;.
has a financial relationship (Stock Options) with Amphivena;.
Speaker/Topic Presenter(s)

Rahul Banerjee, MD, FACP

has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.
has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Guidepoint Global;.

Ryan Cassaday, MD

has a financial relationship (Grant Or Contract) with Kite;.
has a financial relationship (Grant Or Contract) with Vanda;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Grant Or Contract) with Servier;.
has a financial relationship (Independent contractor) with Jazz;.
has a financial relationship (Independent contractor) with Autolus;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Other) with Autolus;.

Mengyang Di, MD, PhD

has no relevant financial relationships to disclose at this time.

Danai Dima, MD

has no relevant financial relationships to disclose at this time.

Bita Fakhri, Bita Fakhri, MD, MPH

has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Loxo/Lilly;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Adaptive;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with BMS/Juno;.

Alexandre Hirayama, MD

has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Grant Or Contract) with Juno Therapeutics, a Bristol Myers Squibb Company;.

Mary Kwok

has a financial relationship (Independent contractor) with BMS;.

Vidhya Nair, DO

has no relevant financial relationships to disclose at this time.

Christina Poh, MD

has a financial relationship (Other) with Acrotech;.
has a financial relationship (Other) with Dren Bio;.
has a financial relationship (Other) with Astex;.
has a financial relationship (Other) with Ipsen;.
has a financial relationship (Other) with Seagen;.

Mei Wei, MD

has a financial relationship (Other) with Relay therapeutics;.
has a financial relationship (Other) with Seagen;.
has a financial relationship (Other) with Arvinas;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Astrazeneca;.
Case Presenter(s)

Ashley Fuller, MD, IF, MSCP

has a financial relationship (Professional Services) with Astellas Pharmaceuticals;.

Livia Hegerova

has a financial relationship (Grant Or Contract) with Rigel;.
has a financial relationship (Grant Or Contract) with Agios;.
has a financial relationship (Grant Or Contract) with Sanofi;.

Fernanda Musa, MD MS

has a financial relationship (Professional Services) with GSK ;.
has a financial relationship (Professional Services) with Duality Bio/ BioNTech;.
has a financial relationship (Professional Services) with OncLive;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Professional Services) with Topline Bio;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with AADI;.

Matthew Schwede, MD, MS

has no relevant financial relationships to disclose at this time.

Michaela Tsai, MD

has no relevant financial relationships to disclose at this time.

Xiaowen Wang, MD, PhD

has no relevant financial relationships to disclose at this time.

Acknowledgement of Commercial Support

This activity is supported with Independent Medical Education grants from:

  • Exact Sciences
  • Incyte

Available Credit

  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$250.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.